

EPIDEMIOLOGY & RISK FACTORS

Lichen Sclerosus and Sexual Dysfunction: A Systematic Review and Meta-Analysis



Rachel Pope, MD, MPH,¹ Min Ho Lee, MD,² Anna Myers, APRN-CNP, MSN,¹ Junmin Song, MD,³ Ramy Abou Ghayda, MD, MPH,¹ Jong Yeob Kim, MD,² Sung Hwi Hong, MD, MPH,⁴ Se Bee Lee, MS,⁵ Ai Koyanagi, MD, PhD,^{6,7} Louis Jacob, MD, PhD,^{6,8} Lee Smith, PhD,⁹ and Jae Il Shin, MD, PhD¹⁰

ABSTRACT

Background: Lichen sclerosus (LS) is a common autoimmune dermatological condition that is often under-diagnosed in women and has been documented to affect quality of life and sexual function.

Aim: To determine the prevalence of sexual dysfunction among women with vulvar lichen sclerosus.

Methods: The authors conducted a systematic review and meta-analysis of the existing research on LS and sexual function in database including PubMed using search terms: lichen sclerosus OR vulvar lichen sclerosus OR vulvar lichen sclerosus et atrophicus OR kraurosis vulvae) AND (sexual function OR sexual functions OR sexual disorder OR sexual disorders OR sexual activity OR sexual activities OR sexual dysfunction OR sexual dysfunctions OR dyspareunia OR vaginismus).

Outcomes: Nearly 60% of women with lichen sclerosus suffer from sexual dysfunction.

Results: Two hundred and ten studies were initially identified. Twenty-six articles met inclusion criteria and 3 were excluded as they did not relate to sexual function, were regarding a surgical or medical intervention and sexual dysfunction and one was a review article. Therefore, 23 studies were included in the final analysis resulting in a cumulative 486 participants with LS with 208 patients experiencing any kind of sexual dysfunction. Meta-analysis presented prevalence of sexual dysfunction among LS patients as 59% (95% CI: 48 – 70%). Dyspareunia or generalized pain with intercourse was the most commonly reported type of dysfunction.

Clinical Implications: Discussing sexual concerns with women with LS could empower them to seek treatment.

Strengths and Limitations: Few articles met criteria for inclusion.

Conclusion: A large proportion of women with LS experience sexual dysfunction. More research is needed, especially that which includes biopsy-proven LS and validated tools on sexual function. **Pope R, Lee MH, Myers A, et al. Lichen Sclerosus and Sexual Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med 2022;19:1616–1624.**

Copyright © 2022, International Society of Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Key Words: lichen Sclerosus; sexual Dysfunction; Vulvar Dermatoses; Vulvar Disorders

Received February 7, 2022. Accepted July 22, 2022.

¹Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA;

²Yonsei University College of Medicine, Seoul, Republic of Korea;

³Keimyung University School of Medicine, Daegu, Republic of Korea;

⁴Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea;

⁵Ulsan University College of Medicine, Seoul, Republic of Korea;

⁶Parc Sanitari Sant Joan de Deu/CIBERSAM, ISCIII, Universitat de Barcelona, Fundació Sant Joan de Deu, Sant Boi de Llobregat, Barcelona, Spain;

⁷ICREA, Barcelona, Spain;

⁸Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France;

⁹Center for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK;

¹⁰Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea

Copyright © 2022, International Society of Sexual Medicine. Published by Elsevier Inc. All rights reserved.

<https://doi.org/10.1016/j.jsxm.2022.07.011>

INTRODUCTION

Lichen sclerosis (LS) is an autoimmune dermatological condition that affects the vulva and vagina in approximately 1 out of 60 women in gynecological clinics.¹ Onset generally occurs around the age of menopause but may occur in prepubertal children and women at younger ages. Its hallmark characteristics include labia minora flattening and loss of architecture, clitoral fusion, and vulvar atrophy. There is also a small risk that it develops to squamous cell carcinoma. It is commonly associated with burning and pruritis, but those symptoms are not universal. Nevertheless, anatomic changes, inflammation, scarring, and narrowing of the vaginal introitus as well as the presence of erosions and fissures are some of the chronic manifestations that can severely affect one's quality of life. Due to the nature of the condition, women with LS may experience dyspareunia, decreased orgasm, and decreased coital frequency.

The condition appears as white, fragile, skin patches that can have a shiny and smooth surface. If LS is untreated the condition can worsen to include complete fusion of the clitoral prepuce, burying the clitoris, anterior and posterior fourchette fusion, complete resorption of the labia minora, skin erosion and ecchymosis.² Unfortunately, LS is a skin disease with no curative treatment and so far the most effective treatments only lessen the symptoms, hopefully causing remission with the mainstay of therapy being high potency topical steroids.

Unfortunately, for many women, in addition to pain with intercourse, they experience an overall negative effect on their intimate relationships due to LS despite treatment and continue to have significant sexual dysfunction.³ Standard treatments are directed at relieving symptoms, therefore, sexual concerns are not always addressed and side effects from the topical steroids may cause additional problems. There are a multitude of factors affecting women's sexual health and quality of life with LS. This includes distress regarding anticipated vulvar symptoms from having intercourse, dissatisfaction with the appearance of genitalia, and diminished sexual function due to physical changes of the vulvar architecture. However, this topic has been generally under-studied and contributes to the limitations for treatment options, especially for cases refractory to topical steroids.

To date, little research on the impact of LS on sexual function is available. A systematic review investigating the effects of LS on sexual dysfunction in women has yet to be conducted. Understanding the impact of this dermatologic condition in sexual health is necessary to improving treatment outcomes of women with LS. Therefore, this study's objective is to review the literature of LS and sexual function.

MATERIALS AND METHODS

Literature Search Strategy and Eligibility Criteria

In this study, the methods have been developed according to the Preferred Reporting Items for Systemic Review and Meta-

Analyses (PRISMA) statement. Investigators (JIS and MHL) independently searched primarily on PubMed from database inception to July 31, 2021. The articles which assessed sexual dysfunction among the women suffering from LS were selected. Search terms used were (lichen sclerosis OR vulvar lichen sclerosis OR vulvar lichen sclerosis et atrophicus OR kraurosis vulvae) AND (sexual function OR sexual functions OR sexual disorder OR sexual disorders OR sexual activity OR sexual activities OR sexual dysfunction OR sexual dysfunctions OR dyspareunia OR vaginismus). The investigators consecutively examined the titles and abstracts and then the full-text. Additionally, the investigators manually searched the references of the selected articles to search out for additional eligible studies. Articles were reviewed by investigators and determined for final inclusion by all. If there was a discrepancy, discussion within the investigators and another author (RP) were performed.

We included studies examining the association between LS and sexual dysfunction, including studies focusing on LS patients with sexual dysfunction, studies comparing sexual prevalence in LS group, studies focusing on the surgical or medical treatment among severely progressed LS, and studies comparing LS with other diseases that contribute to sexual dysfunction such as vulvar lichen planus. We did not apply limitations in study design and included clinical trials, observational studies, case series, letters, and interviews. We defined LS as clinically or pathologically diagnosed LS. The definition of sexual dysfunction was based on the definition used in original articles. We compared sexual function tools and scores when possible. We excluded studies that specifically looked at sexual function as an outcome after an intervention such as surgery, laser or other experimental treatment. The risk of bias was evaluated using the Newcastle Ottawa Quality Assessment Scale (Table 4).

Data Extraction

From each eligible article, we extracted the name of the first author, publication year, study design, definition of sexual dysfunction of each articles, and total number of LS patients, and cases suffering from sexual dysfunction, biopsy confirmation of LS diagnosis, usage of Female Sexual Function Index (FSFI) score, usage of Female Sexual Distress Scale (FSDS) score, adjustment of outcome and reference index (Table 1). We performed a meta-analysis to aggregate prevalence of sexual dysfunction within the patients suffering from LS. In calculating prevalence, we excluded studies focusing on the treatment of sexual dysfunction, because all of the LS patients had sexual dysfunction, which would exaggerate the prevalence of sexual dysfunction in LS. We extracted prevalence of sexual dysfunction among LS patients.

Statistical Analysis

From the each included study, we calculated prevalence of sexual dysfunction among the LS patients. In the each study, the prevalence and variance was calculated and meta-analysis was

Table 1. Characteristics of studies included in the systemic review

Study	Study design	Definition of sexual dysfunction	Total number of LS patients	Number of cases with sexual dysfunction	Biopsy status	Single/Multi center	FSFI	FSDS	Adjustment of outcome	Ref
Sadownik et al., 2020 ⁴	Interview	NA	7	NA	Not mentioned	Single center			NA	10
Brauer et al., 2016 ⁵	Interview	Sexual pain or decreased sexual activity	19	NA	Not mentioned	Single center			NA	5
Simpkin et al., 2007 ⁶	Other (consultation and retrospective chart review)	Sexual problems including dyspareunia and apareunia	202	90	Mainly clinical diagnosis, biopsy if needed	Single center			NA	12
Chmel et al., 2019 ⁷	Prospective cohort study	FSFI score < 26.55	9	NA	Biopsy confirmed	Single center	*	*	NA	17
Burger et al., 2016 ⁸	Case series	NA	23	NA	Biopsy confirmed	Single center			NA	16
Corazza et al., 2020 ⁹	Retrospective cohort study	Dyspareunia	90	51	Not mentioned	Single center			NA	6
Dalziel et al., 1995 ¹⁰	Survey	Dyspareunia, Reduced frequency of intercourse, Apareunia, Orgasm altered, Relationship affected	45	34	Not mentioned	Single center			NA	7
Yildiz et al., 2020 ¹¹	Prospective cohort study	FSFI score < 26.55	59	NA	Biopsy confirmed	Single center	*		NA	25
Schwegler et al., 2011 ¹²	Survey	NA	96	NA	Biopsy confirmed	Single center			NA	21
Gordon et al., 2016 ¹³	Other	FSFI score < 26	16	NA	Not mentioned	Single center	*		NA	8
Richardson et al., 2005 ¹⁴	Letter	NA	NA	NA	Not mentioned	Single center			NA	9
Lauber et al., 2021 ¹⁵	Retrospective observational study	Dyspareunia, Apareunia, Orgasm altered, Introitus stenosis	41	NA	Biopsy confirmed	Single center			NA	19
Flynn et al., 2015 ¹⁶	Retrospective chart review	Low degree of satisfaction and deterioration in sexual functioning	25	NA	Biopsy confirmed	Single center			NA	18
Corazza et al., 2020 ¹⁷	Cross-sectional study	NA	87	NA	Biopsy confirmed	Single center			NA	15
Cheng et al., 2017 ¹⁸	Prospective cohort study	Low FSFI, FSDS score (cutoff score not clarified)	24	NA	Mainly clinical diagnosis, biopsy if needed	Single center	*	*	NA	11
Skrzypulec et al., 2009 ¹⁹	Clinical trial	FSFI score < 26.55, Score in each domain ≤ 3.9 (FSFI)	37	NA	Biopsy confirmed	Single center	*		NA	22
Rangatchew et al., 2017 ²⁰	Other	Dyspareunia, Apareunia	38	NA	Biopsy confirmed	Single center			NA	20
Van et al., 2010 ²¹	Survey	FSFI score < 26.55 FSDS score > 15	215	NA	Biopsy confirmed	Single center	*	*	NA	24
Gutierrez et al., 2019 ²²	Letter	FSFI score < 26	20	14	Biopsy confirmed	Single center	*		NA	14
Haefner et al., 2014 ²³	Case-control study	Pain and itching, Low sexual activeness, Unsatisfactory sexual activity, Low frequency of orgasm	197	NA	Biopsy confirmed	Single center			NA	26
Burrows et al., 2011 ³	Clinical trial	FSDS score > 15	36	NA	Biopsy confirmed	Single center		*	NA	3
Felmingham et al., 2020 ²⁴	Retrospective chart review	NA	109	NA	Biopsy confirmed	Single center			Age, Duration since the onset of symptoms, Being sexually active	23
Yang et al., 2018 ²⁵	Retrospective chart review	Negative effects on sexual function (varying symptoms)	129	71	Mainly clinical diagnosis, biopsy if needed	Single center			NA	13

FSDS = female sexual distress scale; FSFI = female sexual function index; LS = lichen sclerosis.

done. The summary prevalence and its 95% confidence interval was estimated. We calculated heterogeneity between the studies by using I^2 value.²⁶ The software used for the analysis were R ver.4.0.4 and its packages.

RESULTS

A PRISMA diagram of the study process is presented in Figure 1. A total of 210 potentially eligible studies were initially identified. Ten studies were excluded due to duplication. 175 studies were excluded due to inappropriate title and abstract and one study was added through additional search. Twenty-six studies met inclusion criteria and 3 were excluded as they did not relate to sexual dysfunction and one was a review article. Therefore, 23 studies were finally eligible, corresponding to 1,524 LS participants.

The definition of LS varied throughout the eligible studies (Table 1). Out of 23 studies, 14 studies were conducted with

biopsy-proven LS. In six studies^{4,5,9,10,13,14} use of histopathological diagnosis were not mentioned, and the remaining three studies^{6,18,25} mainly used clinical diagnosis as their prior method and only used biopsy when necessary.

In the eligible studies, we could only use five studies^{9,10,6,22,25} to calculate the prevalence of sexual dysfunction in the patients suffering from LS. It was not possible to use the other 18 studies because of the following reasons: three^{13,4,17} did not have a precise definition of sexual dysfunction, 9 studies^{3,5,7,8,12,15,16,19,20} were focused on the surgical or medical treatment of severely progressed LS, such as vulvar adhesions. Five studies^{14,18,11,21,24} did not present the raw data and one remaining paper²³ was a case-control study.

The summary of results and number of patients in those five calculable studies are presented on Table 2. In these five studies, which included a consistent definition of women with sexual dysfunction with the women suffering from LS, the total number of patients with LS is 486 and within those patients, 208 patients




Figure 1. PRISMA flow diagram.

Table 2. Summary of the results of the studies on the prevalence of sexual dysfunction in lichen sclerosis patients

Study	Results of the study	Number of patients		Ref
		Sexual dysfunction	LS patients	
Simpkin et al., 2007 ⁶	101 of 185 patients (56%) with biopsy-confirmed vulval lichen sclerosus were asymptomatic but 22 (12%) continued to have moderate to severe symptoms	90	202	12
Corazza et al., 2020 ⁹	Dyspareunia occurred in more than half of vulvar lichen sclerosus patients	51	90	6
Dalziel et al., 1995 ¹⁰	The majority of women of all ages reported that lichen sclerosus had a detrimental effect on sexual function with problems including dyspareunia, apareunia and difficulty achieving orgasm	34	45	7
Gutierrez et al., 2019 ²²	Patients with vulvar LS experience female sexual dysfunction, so it is essential to consider their quality of life related to sexual well-being when devising treatment and care plans for them	14	20	14
Yang et al., 2018 ²⁵	Chinese patients, with a few asymptomatic individuals, follow a normal distribution for the age of onset, with a peak at age 25–30 y, and these patients have less comorbid autoimmune diseases, incidence of dysuria, constipation and squamous cell carcinoma	71	129	13

FSDS = female sexual distress scale; FSFI = female sexual function index; LS = lichen sclerosus; SD = standard deviation.

presented sexual dysfunction. Meta-analysis was performed among these five studies (Table 3), presenting the prevalence of sexual dysfunction among LS patients. In random effects estimates the prevalence was 0.59(95% CI: 0.48–0.70), and in fixed effects estimates the prevalence was 0.54(95% CI: 0.50–0.59). A forest plot was drawn (Figure 2) presenting that about 59% LS patients suffer from any kind of sexual dysfunction. Dyspareunia and generalized pain with intercourse was the most commonly reported dysfunction. Apareunia and difficulty achieving orgasm were also present in LS patients.

Within the included studies, higher quality studies included control groups and used validated measures for sexual function, most commonly the FSFI and FSDS. Beck Anxiety Index (BAI),¹¹ Female Genital Self-Image Scale(FGSIS),¹¹ Pictorial Representation of Illness and Self Measure(PRISM),¹⁷ Vulval-disease Quality of Life Index(VLQI)²⁴ were also used in each of the articles, but these measures were not included in the remaining studies. Unfortunately, there are not enough studies that use the same validated measures in order to combine data for larger power. However for those that did include FSFI, the score of patients suffering from LS were significantly lower than controls.^{21,11}

In Yildiz, Cengiz et al.,¹¹ 59 patients suffering from vulvar LS were included and had a FSFI score of 17.90, which was significantly lower(P value < .01) than the score of healthy control group(28.50, n = 50). In Van de Nieuwenhof, Meeuwis et al.,²¹ 187 patients with LS had a mean total FSFI score of 18.79, which was significantly(P value <.001) lower than that of the control group(27.43, n = 187). Plus, FSDS score was significantly(P value < .001) higher in the LS patient group (mean = 26.08) compared to the control group (mean = 9.97). These results indicate that LS patients have worse sexual function and higher distress compared to the healthy individuals.

Patients suffering from LS also suffered from low quality of life^{18,20,12,24,21} and the main reason for the deterioration was due to sexual difficulties and was not because of impact on working or studying.²¹ Two studies^{18,21} used Dermatologic Life Quality Index(DLQI) score to measure quality of life, which has a high score in patients with low quality of life.²¹ Since the scoring system is based on the effect of dermatologic conditions on the quality of life, it is not possible to measure DLQI scores on the healthy control group. In spite of that, LS patients had high DLQI scores of 3.79(SD: 4.98, n = 48)¹⁸ and 11.92(SD: 6.18, n = 215)²¹ in the selected studies, indicating LS patients are

Table 3. Summary of the meta-analysis results on the prevalence of sexual dysfunction in lichen sclerosis patients

	Number of studies	Random effects estimate and 95% confidence interval	Fixed effects estimate and 95% confidence interval	I ² and P value for Q test	Egger P -value
Proportion of sexual dysfunction among lichen sclerosis patients	5	0.59 (0.48 to 0.70)	0.54 (0.50 to 0.59)	82% (< .001)	.014

LS = lichen sclerosis.




Figure 2. Random-effect meta-analysis forest plots representing the prevalence of sexual dysfunction among LS patients.

suffering from low quality of life. One study¹² used Skindex-29 score and Patient Benefit Index(PBI) score, and also suggested that LS patients have problems in their quality of life.

Several studies^{5,7,15,16} focused on surgical and other interventional treatments to resolve sexual dysfunction among severely progressed LS patients. In those studies, surgery of the severe LS with adhesions or phimosis showed high satisfaction among the patients. In those selected patients, LS surgery improved sexual dysfunctions and decreased distress regarding sexual function and most of the patients were satisfied with the effect of the surgery among their sexual dysfunction.

In Brauer, van Lusen et al.,⁵ patients with clitoral phimosis from LS underwent surgery. Thirteen out of 19 LS patients (68.4%) improved from sexual pain after receiving LS surgery. In Chmel, Nováčková et al.,⁷ 9 patients with severe LS complicated by clitoral phimosis had gone through LS surgery, and after 12 months those patients had significant improvement of FSFI score from 17.9 ± 0.9 to 26.6 ± 0.5 (P value $< .001$). FSDS score were also reduced significantly from 33.8 ± 6.9 to 21.3 ± 6.2 (P value $< .001$). In Lauber, Vaz et al.,¹⁵ 37 out of 41 LS patients receiving perineoplasty had satisfaction from the LS surgery, and there was a significant reduction of dyspareunia. Similar result were shown in Flynn, King et al. 2015¹⁶. In this study, LS surgery was performed in 25 LS patients suffering from complications of vulvar granuloma fissuratum. Four to 130 months after the surgery, patients were interviewed by telephone about their satisfaction about their postsurgical state. 11(44%) patients replied as 'Very satisfied' about the surgery, and 10 (40%) patients replied 'Satisfied'. Only 4(16%) patients replied they were 'Not satisfied' about the surgery. Of the 25 patients, 21 (84%) patients indicated that they would recommend surgery to another women with similar symptoms. In addition, topical laser on the affected area also improves sexual function among the LS patients suffering from sexual dysfunction.¹⁹ However, these interventional studies were all so variable that they were not

included in the meta-analysis of the prevalence of sexual function of women with LS.

DISCUSSION

Sexual dysfunction is one of the most important symptoms caused by LS. Because of the social taboo regarding sex, and because of other bothersome symptoms such as pruritus and discoloration, patients and researchers tend not to focus on sexual dysfunction. However, upon interview,^{5,4} if physicians ask inquisitively about patients' symptoms, we see that many LS patients suffer from sexual dysfunction. Sexual dysfunction is a major problem itself, and it can also affect the quality of life and mental health of women.

While there are relatively few studies on women with LS and sexual dysfunction, it is clear that a large proportion of women with LS suffer from pain with sexual intercourse among other sexual dysfunctions. From 23 eligible studies, 5 studies were applicable for estimating prevalence of sexual dysfunction among the LS patients. Within those 479 LS patients of 5 studies, 207 patients suffered from sexual dysfunction, and the meta-analysis suggests about 59% of LS patient may suffer from sexual dysfunction. LS patients most commonly suffered from dyspareunia or generalized pain with intercourse.

There were many scoring systems to assess the sexual dysfunction of LS patients throughout the studies. Few papers used the same validated tools, but for those that did, there is clear indication that those with LS have diminished sexual function and increased distress compared to controls. The most commonly used tools were the FSFI and the FSDS. Two studies^{21,23} imply LS patients have a significantly lower score of FSFI compared to healthy control group. One study,²¹ indicates FSDS score is higher in LS patients than the healthy control group. These results represent the detrimental effects of LS. Quality of life was also assessed in many studies.^{18,20,12,24,21} Many patients suffered

Table 4. Quality assessment Newcastle Ottawa scale

Cohort studies Author, y	Selection			Demonstration that the current outcome of interest was not present at start of study	Comparability Comparability of cohorts on the basis of the design or analysis	Outcome		Total quality score	Ref
	Representativeness of the exposed cohort	Selection of the non- exposed cohort	Ascertainment of exposure			Assessment of outcome	Was follow-up long enough for outcomes to occur		
Sadownik et al., 2020 ⁴		*	*		**	*		6	10
Brauer et al., 2016 ⁵		*	*		**	*		5	5
Simpkin et al., 2007 ⁶		*	*		**	*		5	12
Chmel et al., 2019 ⁷		*	*		**	*	*	6	17
Burger et al., 2016 ⁸		*	*		**	*	*	6	16
Corazza et al., 2020 ⁹		*	*		**	*		5	6
Dalziel et al., 1995 ¹⁰		*	*		*	*		4	7
Yildiz et al., 2020 ¹¹		*	*		**	*		5	25
Schwegler et al., 2011 ¹²		*	*		**	*		5	21
Gordon et al., 2016 ¹³		*	*		**	*		5	8
Richardson et al., 2005 ¹⁴									9
Lauber et al., 2021 ¹⁵		*	*		*	*		4	19
Flynn et al., 2015 ¹⁶		*	*		*		*	4	18
Corazza et al., 2020 ¹⁷		*	*		**	*		5	15
Cheng et al., 2017 ¹⁸		*	*		*	*		4	11
Skrzypulec et al., 2009 ¹⁹		*	*		*	*	*	5	22
Rangatchew et al., 2017 ²⁰		*	*		*	*	*	5	20
Van et al., 2010 ²¹		*	*		**	*		5	24
Gutierrez et al., 2019 ²²		*	*		*	*	*	5	14
Haefner et al., 2014 ²³		*	*		*	*		4	26
Burrows et al., 2011 ³		*	*		*	*	*	5	3
Felmingham et al., 2020 ²⁴		*	*		**	*		5	23
Yang et al., 2018 ²⁵		*	*		**	*		5	13

from deterioration of quality of life and sexual dysfunction was a major factor for the poor quality of life.

In severe LS with adhesions or phimosis, it is well studied that surgical treatments are highly satisfactory to the patients. In many studies,^{5,7,15,16} surgical treatments improve sexual dysfunction and the quality of life of the patients. Also, the patients were willing to recommend the surgery to other patients. From the studies above, FSFI score was significantly increased and FSDS score was significantly decreased after the patients received LS surgery. However, one study²⁰ pointed out that surgical treatment in LS may be good for short term, but relapse of the disease is possible.

This study has some limitations. First of all, the number of studies and patients are small and Egger *P*-value is lower than .05, suggesting that there may be a publication bias. Nevertheless, estimating an approximate prevalence could serve as a foundation for future studies. In addition, presenting a solid number instead of ambiguous words such as 'high' or 'moderate' will draw attention from many physicians and patients, which give them a chance to investigate thoroughly about their hidden symptoms. Secondly, few articles specified whether those included had biopsy-proven LS. According to American College of Obstetricians and Gynecologists (ACOG), except in prepubertal children, since other vulvar diseases can mimic LS, a biopsy is necessary to confirm diagnosis of LS.²⁷ Most of the eligible studies used biopsy-proven LS when enrolling their patient group. However some studies did not evince their use of biopsy and some studies only used biopsy when needed. Thirdly, uniform scaling index of sexual dysfunction and distress were not used throughout the study.

In general, due to the scant research but remarkable findings on the negative sexual experience of those with LS, more robust research is needed. Specifically, it would be helpful to include individuals with biopsy-proven LS and to use widely-used validated tools such as FSFI and FSDS in order to compare findings to other studies and continue to learn more about the pathophysiology of the condition in order to eventually reach improved treatment options.

CONCLUSION

Among the patients suffering from LS, there is a high prevalence (approximately 59%) of sexual dysfunction. The mean FSFI score were lower in LS group compared to healthy control groups and the mean FSDS score were higher in LS group compared to healthy control groups, which indicates that LS is associated with lower sexual function and higher sexual distress. Quality of life was also deteriorated in LS patients and main reason was the sexual dysfunction. In LS patients with vulvar adhesion surgery improved sexual function significantly but may suffer from relapse. We suggest continuing to develop a staging system for LS in order to correlate clinical findings to patient experience such as sexual function and quality of life. We also suggest further research into the mechanism of vulvovaginal

changes in order to improve treatment and quality of life of those living with LS.

Corresponding Author: Jae Il Shin, MD, PhD, Department of Pediatrics, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, C.P.O. Box 8044, Seoul 120-752, Republic of Korea. Tel: +82-2-2228-2050; Fax: +82-2-393-9118; E-mail: shinji@yuhs.ac

Conflict of Interest: The authors report no conflicts of interest.

Funding: None.

Twitter message: The prevalence of sexual dysfunction among women with lichen sclerosis is 59% (95% CI: 48 – 70%) Discussing sexual concerns with women with LS could empower them to seek and get treatment. Twitter handles: @drpope@AnnaMyersCUNP

STATEMENT OF AUTHORSHIP

Rachel Pope: Conceptualization, Methodology, Investigation, Writing - Original Draft, Writing - Review and Editing, Supervision; Min Ho Lee: Investigation, Investigation, Writing - Original Draft; Anna Myers: Conceptualization, Methodology, Investigation, Writing - Original Draft, Writing - Review and Editing; Jun Min Song: Writing - Review and Editing, Supervision; Ramy Abou Ghayda: Conceptualization, Methodology, Writing - Review and Editing; Jong Yeob Kim: Writing - Review and Editing; Sung Hwi Hong: Conceptualization, Methodology, Investigation, Writing - Original Draft, Writing - Review and Editing; Se Bee Lee: Writing - Review and Editing; Ai Koyanagi: Writing - Review and Editing; Louis Jacob: Writing - Review and Editing; Lee Smith: Writing - Review and Editing; Jae Il Shin: Conceptualization, Methodology, Investigation, Writing - Review and Editing.

REFERENCES

1. Goldstein AT, Marinoff SC, Christopher K, et al. Prevalence of vulvar lichen sclerosis in a general gynecology practice. *J Reprod Med* 2005;50(7):477-480.
2. Powell JJ, Wojnarowska F. Lichen sclerosis. *Lancet* 1999;353(9166):1777-1783.
3. Burrows LJ, Creasey A, Goldstein AT. The treatment of vulvar lichen sclerosis and female sexual dysfunction. *J Sex Med* 2011;8(1):219-222.
4. Sadownik LA, Koert E, Maher C, et al. A qualitative exploration of women's experiences of living with chronic vulvar dermatoses. *J Sex Med* 2020;17(9):1740-1750.
5. Brauer M, van Lunsen RH, Laan ET, et al. A qualitative study on experiences after vulvar surgery in women with lichen sclerosis and sexual pain. *J Sex Med* 2016;13(7):1080-1090.
6. Simpkin S, Oakley A. Clinical review of 202 patients with vulval lichen sclerosis: a possible association with psoriasis. *Australas J Dermatol* 2007;48(1):28-31.

7. Chmel R, Nováčková M, Fait T, et al. Clitoral phimosis: effects on female sexual function and surgical treatment outcomes. *J Sex Med* 2019;16(2):257–266.
8. Burger MP, Obdeijn MC. Complications after surgery for the relief of dyspareunia in women with lichen sclerosis: a case series. *Acta Obstet Gynecol Scand* 2016;95(4):467–472.
9. Corazza M, Virgili A, Minghetti S, et al. Dyspareunia in vulvar lichen sclerosis: an overview of a distressing symptom. *G Ital Dermatol Venereol* 2020;155(3):299–305.
10. Dalziel KL. Effect of lichen sclerosis on sexual function and parturition. *J Reprod Med* 1995;40(5):351–354.
11. Yıldız Ş, Cengiz H, Kaya C, et al. Evaluation of genital self-image and sexual dysfunction in women with vulvar lichen planus or lichen sclerosis. *J Psychosom Obstet Gynaecol* 2020;43(2):99–106.
12. Schwegler J, Schwarz J, Eulenburg C, et al. Health-related quality of life and patient-defined benefit of clobetasol 0.05% in women with chronic lichen sclerosis of the vulva. *Dermatology* 2011;223(2):152–160.
13. Gordon D, Gardella C, Eschenbach D, et al. High prevalence of sexual dysfunction in a vulvovaginal specialty clinic. *J Low Genit Tract Dis* 2016;20(1):80–84.
14. Richardson D, Bell C, Goldmeier D. Lichen sclerosis: are there really no long-term disturbances in sexual function? *Int J STD AIDS* 2005;16(11):774.
15. Lauber F, Vaz I, Krebs J, et al. Outcome of perineoplasty and de-adhesion in patients with vulvar Lichen sclerosis and sexual disorders. *Eur J Obstet Gynecol Reprod Biol* 2021;258:38–42.
16. Flynn AN, King M, Rieff M, et al. Patient satisfaction of surgical treatment of clitoral phimosis and labial adhesions caused by lichen sclerosis. *Sex Med* 2015;3(4):251–255.
17. Corazza M, Virgili A, Toni G, et al. Pictorial representation of illness and self-measure to assess the perceived burden in patients with chronic inflammatory vulvar diseases: an observational study. *J Eur Acad Dermatol Venereol* 2020;34(11):2645–2651.
18. Cheng H, Oakley A, Conaglen JV, et al. Quality of life and sexual distress in women with erosive vulvovaginal lichen planus. *J Low Genit Tract Dis* 2017;21(2):145–149.
19. Skrzypulec V, Olejek A, Drosdzol A, et al. Sexual functions and depressive symptoms after photodynamic therapy for vulvar lichen sclerosis in postmenopausal women from the Upper Silesian Region of Poland. *J Sex Med* 2009;6(12):3395–3400.
20. Rangatchew F, Knudsen J, Thomsen MV, et al. Surgical treatment of disabling conditions caused by anogenital lichen sclerosis in women: an account of surgical procedures and results, including patient satisfaction, benefits, and improvements in health-related quality of life. *J Plast Reconstr Aesthet Surg* 2017;70(4):501–508.
21. Van de Nieuwenhof HP, Meeuwis KA, Nieboer TE, et al. The effect of vulvar lichen sclerosis on quality of life and sexual functioning. *J Psychosom Obstet Gynaecol* 2010;31(4):279–284.
22. Gutierrez-Ontalvilla P, Botella R, Iborra M, et al. The Female sexual function index to assess patients with moderate to severe vulvar lichen sclerosis. *Eur J Dermatol* 2019;29(4):430–431.
23. Haefner HK, Aldrich NZ, Dalton VK, et al. The impact of vulvar lichen sclerosis on sexual dysfunction. *J Womens Health (Larchmt)* 2014;23(9):765–770.
24. Felmingham C, Chan L, Doyle LW, et al. The vulval disease quality of life index in women with vulval lichen sclerosis correlates with clinician and symptom scores. *Australas J Dermatol* 2020;61(2):110–118.
25. Yang M, Wen W, Chang J. Vulvar lichen sclerosis: a single-center retrospective study in China. *J Dermatol* 2018;45(9):1101–1104.
26. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21(11):1539–1558.
27. ACOG. Practice Bulletin No. 93: diagnosis and management of vulvar skin disorders. *Obstet Gynecol* 2008;111(5):1243–1253.